Tag Archives | HCV

Biotech Bear Market Update: Barely Bouncing Off the Bottom

Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35%         XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally then faded with the IBB up 0.625 % […]

Continue Reading 0

Large Cap Biopharmaceuticals Winners and Losers 2015-16: Which Stocks Can Outperform the ETFs in 2016?… Part 1

Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a FED rate rise, with potentially less available equity funding, […]

Continue Reading 0

Valuation Models for Large Cap Biopharma Stocks in a Bear Market

 Valuation Models for Large Cap Biopharma Stocks Can Robust Drug Pipelines Deliver Future EPS Growth? This is a follow-up of our post on 1/8/16 Large Cap Biopharmaceuticals which looks at valuation models and stock performance of selected companies after the J.P.Morgan Healthcare Conference and then again after 2015 earnings reports over the next few weeks. Which […]

Continue Reading 0

Can Large Cap Biopharmaceutical Stocks Outperform in 2016?

 Large Cap Biopharmaceutical Stock Valuations After Correction We previously summarized the Rayno Mid and Small Cap Portfolios for 2015, a good year despite the correction. With this post we summarized selected Sales and Earnings metrics (Source finviz.com) of important large cap biotech stocks for the purpose of analysis after the J.P. Morgan Healthcare Conference and […]

Continue Reading 0

Biotech Bear Market Rally on Hold: Lackluster Tape for Week One 2016…Update-1

Update-1… 3P EST –Biotechs Sink Further XBI Down 5%, IBB down 2.34% Green stocks are hard to find: GILD, HOLX, REGN Biotech Bear Market: Lackluster Tape Says Wait Until Next Week For Market Direction Year-End Rally Fizzles in New Year Biotech stocks (IBB) are off 5% from year-end 2015 highs and up only 6.73% from […]

Continue Reading 0

Bear Market Biotech Rally Is Tradeable…Update-1

Update after close 12/16…IBB up 2.25%, XBI up 4.45% Rayno Life Science Big Movers Rayno Biopharma ABBV up 2.2%,ALKS up 8.12%, BIIB up 3.52%, ARRY up 20.63 %, CRIS up 6.27%, FCSC up 5%, GERN up 4.42%,RXDX up 2.92% and SGEN up 4.93%. Rayno Dx and Tools ABAX up 2.57%, CPHD up 4.87%,GHDX up 2.87% […]

Continue Reading 0

Nasty Day With Big Sell-Off in Healthcare and Biotech

Biotech Sell-Off Stops Bear Market Rally After a strong November and a rally from October lows biotech stocks broke down today along with the overall market. Keep in mind that it has been a bear market rally with expectations of a seasonal move up. There are plenty of possible reasons for the market weakness both […]

Continue Reading 0

Biotech Rally Underway Trying to Overcome Gloomy Macro Data…Update-1

Update 11/16 PM Biotech Rally Underperforms Energy up 2.99% and Telecom up 1.81% The S&P and Dow rallied past Paris attack and terrorism concerns after an early morning stall. Biotechs underperformed weighed down by the Clovis Oncology (CLVS) NDA delay. The IBB was up 0.39% in a choppy session. Among the losers were mid-caps awaiting […]

Continue Reading 0

Rayno Life Science Recap Week Ending 11/6: Small Cap Biopharmaceuticals Outperform

Small Caps Hot, Large Caps Not Curis (CRIS) and Fibrocell Science (FCSC) Lead the Way Up Biotech stocks could not extend last month’s rally in choppy trading that left major indices up but off mid-week highs. The healthcare sector sold off on continued pricing concerns with bad news Valeant (VRX) still in the forefront and […]

Continue Reading 0

Large Cap Biotech Stocks Get Traction From Revenue Growth…Update-1

10/29/15 Update Large Cap Biotechs Update Amgen (AMGN) Revenues Grow 14%, beats street. 2016 Revenues guided to ~$22B, flattish revenue growth with higher EPS $10.35-$10.75. 2015 PEG=1.80, P/S=5.94, Div. 1.94% Rayno Biopharmaceutical Portfolio Large Caps up 2.6% YTD, IBB up 8% YTD REGN up 37%, GILD up 16%, AMGN up o.6% ABBV ALXN BIIB RHHBY […]

Continue Reading 0

Sector Shift Continues Out of Healthcare Stocks: Update-1

Summary for the Week of Oct 19:Markets Up on Central Banks Easing;Techs Lead the Way IBB up 0.62%- 316.3  bottomed on Wednesday. QQQ up 4.3%- 112.78 up big Thursday and Friday. XBI down o.58%- 65.67  in choppy trading. XLI up 4%- 54.66 steady climb from Monday. XLV down 0.62% 69.33 bottomed on Thursday ———– Healthcare Stocks […]

Continue Reading 0

Choppy Action Today in Biotech Stocks But Buyers Are Out There…Update-1

October 21  Update 9:45a EDT NASDAQ up 0.4% IBB up 1.57% 1:45p EDT Biotech Thrashing Continues-High Fliers Hit Hardest Healthcare stocks remain under attack with the XLV down 1.5% and the IBB down 1.6%.Healthcare is the sector loser down 2% while the Industrials are up slightly. Large cap Biogen (BIIB) is still up 2.5% after […]

Continue Reading 0

Biotech Bear Market: After the bubble burst…Update-1… 10/15 Rally

10/15 After the Close… XBI Up 7.26%…Green Screen…MOmentum is back Biotech stocks soared today in a broad rally showing a good appetite especially for small and mid-cap stocks. This could be a counter-trend rally in a biotech  bear market but there is a lot of money on the sidelines ready to be put to work. […]

Continue Reading 0

Biotech Bear Market Trends #5: Update-3

Another Rally from FED minutes…except biotech 10/8/15 … BIOTECH-Another test near 2015 lows in early AM ; choppy downtrend but look for a bottoming process as market is turning up toward close: IBB at 306 down slightly after reversal XBI down 1.7% to 63.3 XLV now green 10/5  9 AM …Rally Should Continue for Third […]

Continue Reading 0

Biotech ETFs Up YTD But 12% Losses in August Creates Downtrend…Update-2.. 9/4

Update -2… 9/8 Rally Time Today Forecasted by Friday’s Action ETF Summary -One month and YTD % FBT (12.36), +9.2% IBB (8.9), +11.3% XBI (10.12), +17.27% The five star Fidelity Select Biotech Portfolio (FBIOX) pretty much tracks the IBB up 11.66% YTD and down (8.52) for one month. Three relatively new top ten mid-cap holdings […]

Continue Reading 0